CD&R Leads Acquisition Race for Stada at €11 Billion

CD&R Leads Acquisition Race for Stada at €11 Billion

Adriana Rossi
2 min read

CD&R Leads Race to Acquire German Drugmaker Stada Valued at €11 Billion

Clayton Dubilier & Rice (CD&R) is taking the lead in the pursuit to acquire Stada, a German pharmaceutical company valued at €11 billion. This comes as current owners Bain Capital and Cinven, who acquired Stada for €5.3 billion in 2017, explore alternative options including a stock-market listing or a minority stake sale if the bids fall short of their expectations. Stada, renowned for products such as Snup, Nizoral, and Grippostad, has garnered attention from private equity firms due to its diverse portfolio and longstanding market presence.

Key Takeaways

  • CD&R is at the forefront of the bidding war for Stada, with a valuation of €11 billion.
  • Bain Capital and Cinven are contemplating a stock-market listing if bid offers are not satisfactory.
  • Stada was acquired by Bain and Cinven in 2017 for €5.3 billion.
  • KKR & Co. and CVC Capital Partners have also expressed interest in acquiring Stada.
  • Bain and Cinven are considering an exit strategy involving a minority stake sale.


The potential acquisition of Stada by CD&R could potentially redefine the pharmaceutical landscape, posing implications for stakeholders such as Bain Capital, Cinven, and other contenders like KKR & Co. and CVC Capital Partners. Should CD&R's bid be successful, there is the potential to leverage Stada's diverse portfolio to broaden market presence, leading to potential improvements in profitability. On the other hand, if Bain and Cinven proceed with a stock-market listing or a minority stake sale, they may encounter challenges in valuation and investor scrutiny. This move by CD&R also signals a trend of private equity firms targeting established pharmaceutical companies for growth and diversification, potentially influencing future M&A activities within the sector.

Did You Know?

  • Clayton Dubilier & Rice (CD&R): A private equity firm recognized for its strategic investments in established companies, with a focus on enhancing operational efficiency and growth. CD&R frequently collaborates with management teams to drive value creation through operational enhancements and strategic repositioning.
  • Stada: A German pharmaceutical company specializing in the production of generic and over-the-counter drugs. Stada's varied portfolio encompasses well-known brands such as Snup (a nasal spray), Nizoral (an anti-dandruff shampoo), and Grippostad (a cold medication), making it an appealing prospect for private equity firms due to its stable revenue streams and market presence.
  • Private Equity Acquisition: A financial transaction in which a private equity firm acquires a controlling interest in a company, often with the intent of improving the company's financial and operational performance before potentially selling it for a profit. This strategy typically involves significant alterations to the company's management, operations, and capital structure.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings